Treatment With Namenda in Women at Risk for Cognitive Decline

This study has been completed.

First Received: October 19, 2005 Last Updated: March 28, 2008 History of Changes

Sponsors and Collaborators:	Stanford University Forest Laboratories
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00242632

Purpose

This research aims to explore the effectiveness of memantine (Namenda) in treating post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline. Memantine has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.

Condition	Intervention
Dementia	Drug: Namenda

MedlinePlus related topics: Dementia

Drug Information available for: Memantine Memantine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Further study details as provided by Stanford University:

Primary Outcome Measures:

6 month score of neuropsychological battery

Estimated Enrollment:	0
Study Start Date:	June 2004

Eligibility

Ages Eligible for Study:	50 Years to 65 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria::

Women between the ages of 50-65
Willing to sign Human Subjects Protection Consent Form
Personal or family history of mood disorder
Hypothyroidism
Diabetes
Family history of Alzheimer's disease Exclusion Criteria:- Possible or probable Alzheimer's disease or dementia
History of cerebrovascular disease
History of myocardial infarction within the previous year
History of unstable heart disease
Uncontrolled hypertension
Less than 8 years of education
English as a 2nd language
Uncorrected vision or hearing deficits

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00242632

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Forest Laboratories

Investigators

Principal Investigator:

Dr Natalie Rasgon

Stanford University

More Information

Additional Information:

Stanford University Behavioral Neuroendocrinology Program This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	95239
Study First Received:	October 19, 2005
Last Updated:	March 28, 2008
ClinicalTrials.gov Identifier:	NCT00242632 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Excitatory Amino Acids
Neurotransmitter Agents
Dopamine
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Memantine

Central Nervous System Diseases
Dopamine Agents
Brain Diseases
Dementia
Cognition Disorders
Delirium

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Nervous System Diseases
Physiological Effects of Drugs
Antiparkinson Agents
Central Nervous System Diseases
Excitatory Amino Acid Agents
Brain Diseases

Pharmacologic Actions
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Therapeutic Uses
Memantine
Dopamine Agents
Dementia
Central Nervous System Agents
Excitatory Amino Acid Antagonists

ClinicalTrials.gov processed this record on May 07, 2009